1. Spotlight on Immuno-Oncology in Melanoma

4. Introduction

5. Emerging Agents Epacadostat

6. Emerging Agents (cont) Epacadostat

7. Emerging Agents OX40

8. Emerging Agents (cont) OX40 Antibody

9. Emerging Agents 4-1BB

10. Emerging Agents 4-1BB Antibody

11. Emerging Agents LAG-3

12. Practical Implications of These Emerging Agents

13. Pembrolizumab Survival Updates KEYNOTE-001

14. Pembrolizumab Survival Updates KEYNOTE-006

15. Notes on Stopping Therapy

16. Combination Nivolumab/Ipilimumab Survival Updates CheckMate-067

17. Upfront Treatment

18. Combination Nivolumab/Ipilimumab Survival Updates CheckMate-069

19. Are Some Patients Cured with Immunotherapy?

20. Treating Patients Who Had Autoimmune Disorders or Preexisting irAEs

21. Treating Patients Who Had Autoimmune Disorders or Preexisting irAEs (cont)

22. Treating Brain Metastases

23. Thoughts on Treating Brain Metastases

24. Sequencing Therapy

25. irAEs and Potential Treatment Benefit

26. Discontinuing Treatment Due to AEs

27. AEs and Treatment Benefit

28. Practical Applications

29. Patients With Wild-Type Disease That Progresses With Immunotherapy

30. A Look to the Future

31. Concluding Remarks

32. Abbreviations

33. Abbreviations (cont)